This, in turn, activates adenylate cyclase and elevates cyclic adenosine monophosphate (cAMP) levels, a mechanism that resembles the defects observed in patients with multiple endocrine neoplasia syndromes (MAS). This evidence concerns the gene ADCY1 and multiple endocrine neoplasia.